Related Experiment Video
Updated: Jul 17, 2026
Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
Published on: June 28, 2018
Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse
Marc Leone1, Frédéric Garcin, Julien Bouvenot
1Intensive Care Unit, Département d'Anesthésie et de Réanimation, Assistance Publique-Hôpitaux de Marseille, Public Hospitals of Marseille, Marseille Medicine University, France.
Objective:
To assess the rate of appropriateness of empirical antimicrobial therapy for ventilator-associated pneumonia, to evaluate de-escalation in patients with ventilator-associated pneumonia treated according to local pathway, and to identify the bacteria responsible for recurrence of ventilator-associated pneumonia.
Design:
Prospective observational study during a 36-month period.
Setting:
Medical-surgical intensive care unit of a university hospital.
Patients:
One hundred and fifteen patients hospitalized in an intensive care unit developing ventilator-associated pneumonia with positive cultures. The patients with ventilator-associated pneumonia were treated with limited-spectrum antibiotics (i.e., without activity against Pseudomonas aeruginosa) if they had no prior hospitalization (within 21 days) or prior administration of antibiotics (within 10 days). Quantitative cultures obtained by bronchoscopy or tracheal aspiration were used to reassess empirical therapy.
Interventions:
None.
Measurements And Main Results:
A limited-spectrum therapy was used in 79 patients (69%). Empirical antimicrobial therapy was appropriate in 100 patients (85%). The mortality rate was significantly higher in the patients in whom empirical therapy was inappropriate than in those in whom treatment was appropriate (47 vs. 20%, p=.04). De-escalation was done in respectively 26% and 72% of patients with early- and late-onset ventilator-associated pneumonia, whereas treatment was escalated in 27 patients (23%). Ventilator-associated pneumonia episodes were recurrent in 22 cases, including eight episodes due to high-risk bacteria.
Conclusions:
A rational empirical antimicrobial therapy for ventilator-associated pneumonia using limited-spectrum antibiotics is possible if local ecology and patient medical history and clinical status are considered. In addition, de-escalation is feasible in 42% of patients. This integrative approach may reduce the emergence of resistant bacteria, which in turns reduces the need for broad-spectrum antibiotics, breaking the vicious circle of antibiotic overuse.
Insights
Rational empirical antimicrobial therapy for ventilator-associated pneumonia (VAP) is achievable by considering local bacterial ecology and patient history. This approach can reduce the emergence of resistant bacteria and antibiotic overuse.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Antimicrobial Stewardship
Background:
- Ventilator-associated pneumonia (VAP) poses a significant challenge in intensive care units.
- Appropriate empirical antimicrobial therapy is crucial for patient outcomes.
- Understanding local bacterial resistance patterns is key to effective VAP management.
Purpose of the Study:
- To determine the appropriateness of empirical antimicrobial therapy for VAP.
- To evaluate the feasibility of antimicrobial de-escalation in VAP patients.
- To identify bacterial causes of recurrent VAP.
Main Methods:
- Prospective observational study conducted over 36 months in a university hospital's medical-surgical intensive care unit.
- Included 115 patients with VAP and positive cultures.
- Limited-spectrum antibiotics were used for patients without recent hospitalization or antibiotic exposure; quantitative cultures reassessed empirical therapy.
Main Results:
- Empirical antimicrobial therapy was appropriate in 85% of patients.
- Limited-spectrum therapy was initiated in 69% of cases.
- Inappropriate empirical therapy was associated with significantly higher mortality (47% vs. 20%).
- De-escalation occurred in 42% of patients; 23% required treatment escalation.
- Recurrent VAP was observed in 22 cases, with eight caused by high-risk bacteria.
Conclusions:
- Tailoring empirical antimicrobial therapy for VAP using limited-spectrum antibiotics, based on local ecology and patient factors, is feasible.
- Antimicrobial de-escalation is achievable in a significant proportion of VAP patients.
- This strategy can mitigate the development of antibiotic resistance and reduce broad-spectrum antibiotic use.
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:29Pneumonia II: Pathophysiology
01:29Pneumonia I: Introduction
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
00:57Antibiotic Selection
01:23Mechanical Ventilation II: Invasive Ventilation
Negative-Pressure Ventilators
Negative-pressure ventilators create a vacuum around the chest or body to draw air into the lungs, simulating breathing. This method does not require an...